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ABSTRACT
Many cancers share specific genetic risk factors including both rare high-penetrance mutations and common single nucleotide polymorphisms (SNPs) identified through genome-wide association studies (GWAS). However, little is known about the overall shared heritability across cancers. Quantifying the extent to which two distinct cancers share genetic origin will give insights to shared biological mechanisms underlying cancer and inform design for future genetic association studies. In this study, we estimated the pair-wise genetic correlation between six cancer types (breast, colorectal, lung, ovarian, pancreatic and prostate) using cancer-specific GWAS summary statistics data based on 66,958 case and 70,665 control subjects of European ancestry. We also estimated genetic correlations between cancers and 14 non-cancer diseases and traits. After adjusting for 15 pair-wise genetic correlation tests between cancers, we found significant (p<0.003) genetic correlations between pancreatic and colorectal cancer (r g =0. 55 , p=0.003), lung and colorectal cancer (r g =0. 31 , p=0.001). We also found suggestive genetic correlations between lung and breast cancer (r g =0. 27 , p=0.009), and colorectal and breast cancer (r g =0. 22 , p=0.01). In contrast, we found no evidence that prostate cancer shared an appreciable proportion of heritability with other cancers. After adjusting for 84 tests studying genetic correlations between cancer types and other traits (Bonferroni-corrected p-value: 0.0006), only the genetic correlation between lung cancer and smoking remained significant (r g =0. 41 , p=1.03x10 -6 ). We also observed nominally significant genetic correlations between body mass index (BMI) and all cancers except ovarian cancer. Our results highlight novel genetic correlations and lend support to previous observational studies that have observed links between cancers and risk factors.
INTRODUCTION
In the US, cancer remains the second leading cause of death with an estimated 1.69 million new cancer diagnoses and 600,000 cancer deaths in 2017 (1) . Six cancer types-breast, colorectal, lung, ovarian, pancreatic and prostate cancer-together constitute more than 50% of annual cancer diagnoses (1) . The etiologies of these cancers are complex and associated heritability estimates (2) from twin studies range between 0.15 (colon) and 0.57 (prostate), indicating genetic components. For pancreatic cancer, data have been too sparse to estimate heritability based on twin studies. However, Mucci and colleagues (2) did observe significant, albeit lower relative to other cancers, familial risks for pancreatic cancer. These results are supported by a meta-analysis based on more than 6,500 cases, where having a relative diagnosed with pancreatic cancer was associated with a 1.8-fold (95% CI: 1.5-2.1) risk increase of pancreatic cancer (3).
Various cancers share both environmental and genetic risk factors including rare high-penetrant mutations in genes such as BRCA2 which predisposes to breast, ovarian, lung, prostate and pancreatic cancers (4). Genome-wide association studies (GWAS) have identified more 350 distinct (reported SNPs > 500kb apart) genomic regions that are associated with cancer (5) of which several are shared between cancer types (6) . For example, the 8q24 (7-9) and TERT (10-13) regions have been associated with multiple cancer types (pleiotropy), although specific alleles often differ. In contrast to pleiotropy, which does not take the direction of association into account, genetic correlation describes the genome-wide correlation in allele effects and thus, considers the allele-specific direction of association between two traits. Thus, the shared genetic etiology between two traits can be either due to a shared genetic variant (or variants) with nonequal non-zero effect sizes (pleiotropy) or via a correlation between effect sizes for causal variants (genetic correlation) (14) . Identifying genetic regions that are associated with multiple cancer types may be useful for determining mechanisms involved in global carcinogenesis.
However, the benefit of simultaneously studying multiple cancer types relies on their genetic correlation.
With the introduction of GWAS, it is now possible to quantify the phenotypic variance explained control subjects obtained from the GAME-ON, PanScan and GECCO consortia. In addition, we estimated the genetic correlation between each of these cancers and 14 non-cancer traits which have all been suggested to be linked to cancer and for which we had access to GWAS summary statistics.
MATERIAL AND METHODS
The GAME-ON network of consortia for post-GWA research, PanScan and GECCO
We utilized three large-scale cancer genetic epidemiological consortia: GAME-ON, PanScan III and GECCO. The Genetic Associations and Mechanisms in Oncology (GAME-ON) consortia is a network of cancer-specific post-GWAS initiatives. The five GAME-ON sites are breast (DRIVE), colorectal (CORECT), lung (TRICL-ILLCO), ovarian (FOCI) and prostate (ELLIPSE) (23) Table 1 . These studies have been described in detail previously (23) . For each cancer type, genotyping was performed using Illumina or Affymetrix arrays of varying densities described elsewhere (23, 26, 27) . For all studies except GECCO, imputation was performed using the 1,000 Genomes Project Phase 1 version 3 reference haplotypes, resulting in up to ~10 million SNPs available for the analysis for each cancer type. For GECCO, data was imputed using an inhouse reference panel of 2,159 whole-genome sequenced European-ancestry GECCO participants (28) . Since imputation quality scores were not readily accessible across all GWAS, we only included HapMap 3 SNPs as a proxy for well-imputed SNPs (29) .
NON-CANCER TRAITS
We also estimated the genetic correlations between the six cancer types and 14 non-cancer traits (29) for which GWAS summary statistics were publicly available (Supplementary Table S1 ).
The included traits were schizophrenia, bipolar disorder, coronary artery disease, type 2 diabetes, Crohn's disease, ulcerative colitis, rheumatoid arthritis, ever/never smoked tobacco, height, BMI, fasting serum glucose, triglycerides, LDL cholesterol and HDL cholesterol. The average sample size for the non-cancer traits was 70,488 subjects.
STATISTICAL METHODS
Associations between SNPs and cancer risk were estimated by unconditional logistic regression adjusted for age, sex (when applicable), and top principal components (ranging from two to six across contributing GWAS) to adjust for potential population stratification. We used a newly developed method for estimating heritability due to common SNPs and genetic correlations that employs only summary statistics together with linkage disequilibrium (LD) information from a reference panel (21, 22) . This method, known as LD score regression, relies on the fact that SNPspecific association statistics reflect the associations of all SNPs in LD with that SNP. Thus, for a polygenic trait, SNPs in high-LD regions will on average have higher χ 2 statistics than SNPs in low-LD regions and similarly, for two polygenic, genetically correlated traits with z-scores z 1 and z 2 , the product z 1 z 2 will on average be higher for SNPs with high LD than SNPs with low LD.
Formally, the relationship between the expected χ 2 statistic for SNP j and the LD score ( ) for SNP j can be described by twin studies), we transformed the observed heritability to the liability scale which takes both ascertainment and disease prevalence into account as previously described (30) . To obtain estimates of cancer-specific prevalence, we used SEER cumulative risks (31) . We can extend the calculations of single-trait heritability to include two traits:
, where is the genetic covariance, 1 and 2 are sample sizes for trait 1 and 2 respectively, is the number of overlapping samples and is the phenotypic correlation in the overlapping samples.
We estimate by the slope of the regression of 1 2 on the LD score and tested for its difference from 0, as described previously (22 We also estimated the genetic correlation between each of these six cancer types and 14 other diseases and traits implicated to be linked to cancer (schizophrenia, bipolar disorder, coronary artery disease, type 2 diabetes, Crohn's disease, ulcerative colitis, rheumatoid arthritis, ever/never smoked tobacco, height, body mass index (BMI), fasting serum glucose, triglycerides, LDL cholesterol and HDL cholesterol ( Figure 1 , Table 3, Supplementary Tables S1 and S3 ). The strongest positive genetic correlation was, as expected, between lung cancer and smoking status (never/ever; r g =0.41, p=1.03x10 -6 ), which was the only correlation to remain significant after adjusting for multiple testing. Other nominally significant genetic correlations with lung cancer were with BMI (r g =0.12, p=0.03) and an inverse genetic correlation with HDL levels (r g =-0.15, p=0.02). For breast cancer, we observed positive genetic correlations with ulcerative colitis (r g =0.24, p=0.002), schizophrenia (r g =0.14, p=0.004) and height (r g =0.14, p=0.01). In contrast, triglycerides (r g =-0.13, p=0.03) and BMI (r g =-0. We used SEER estimates (31) to obtain cancer-specific cumulative risks, recognizing that not all study subjects came from US populations. For comparison, we also calculated the heritability on the liability scale using cumulative risks obtained from Mucci et al (2) . No qualitative difference was observed for the liability estimates using the two different sources of cumulative risks. In concordance with previous studies, the cancer-specific heritability estimates observed here were lower than what has been observed in twin studies. This is not unexpected given that here, we are only estimating the additive genetic component based on common SNPs captured by GWAS, and thus, any contribution to the heritability based on factors such as gene-gene interactions, gene-environment interactions, structural variants or rare variants, will not be captured by our analysis. Among the studied cancers, we observed the largest heritability for prostate cancer (ℎ 2 =0.27) in agreement with previous twin studies (2). We also compared our cancer-specific heritability results to previous studies estimating heritability based on GWAS data. In general, our results were comparable with previous studies. Lu all on the liability scale and were calculated using SEER rates for all three studies including ours.
We found that colorectal cancer showed significant genetic correlations with pancreatic and lung cancers, with the largest genetic correlation observed for the two gastrointestinal tract cancers:
the r g for colorectal and pancreatic cancer was 0.55 (p=0.003). Amundadottir and colleagues studied cancer risk for first up to fifth degree relatives in an Icelandic population and observed an increased risk for pancreatic cancer among colon cancer patients (and vice versa) for first degree relatives but not beyond (32) . Colorectal cancer patients have been observed to have a higher incidence of pancreatic cancer than the general population (33) . Further, Lynch syndrome, the most common hereditary colorectal cancer syndrome, has also been shown to increase risk for pancreatic cancer (34) . Obesity is a well-established risk factor for both colorectal and pancreatic cancer (35,36) and we observed nominally significant (p<0.05) genetic correlations between BMI and both colorectal and pancreatic cancer.
Colorectal cancer also showed suggestive genetic correlation with breast cancer in agreement with the study from Amundadottir and colleagues (32) . A recent study found that women diagnosed with breast cancer have a 1.59-fold (95% Confidence Interval (CI): 1.53-1.65) increased risk of developing colorectal cancer compared to the general population (37).
Breast and lung cancer showed a suggestive positive genetic correlation (r g =0.27, p=0.009), supported by observational studies finding familial co-segregation of the two cancers (38, 39) as well as overlap in multiple susceptibility genes such as BRCA2, CHEK2 (40) and LSP1 (7) . In contrast, Amundadottir and colleagues did not observe a significant cooccurrence among relatives (32) . A recent cross-cancer GWAS based on the GAME-ON data (23) identified a pleiotropic locus at 1q22 that was associated with both breast and lung cancer.
We expect these results to generate testable hypotheses about mechanisms. There are data to support inflammation response, DNA repair and stress responses, to list just a few. For example.
the genetic correlations between breast, colorectal and lung cancer might be driven in part by genetic variants in the inflammation pathway. Indeed, a recent analysis of genetic variation in the inflammation pathway from the GAME-ON consortium identified SH2B3, a key negative regulator of cytokine signaling to be associated with all three cancers (41 it is likely that the genetic correlations that we observe are due to yet unidentified SNPs, and future studies should focus on simultaneously study genetically correlated cancers with the goal of identifying SNPs that are associated with multiple cancer types.
We did not observe evidence that either ovarian or prostate cancer shared an appreciable amount of heritability with other cancers, although our sample size for ovarian cancer was relatively small, leading to wide confidence intervals. We had higher statistical power to detect genetic correlations involving prostate cancer, but no estimate was >0.1, suggesting that prostate cancer has a genetic contribution that is distinct from that of other cancer types studied here. Witte and Hoffmann used polygenic risk scores to investigate a potential shared heritability between breast and prostate cancer, and although they observed a potential common polygenic model between non-aggressive prostate cancer and breast cancer, they observed no evidence of a common model between overall prostate cancer and breast cancer, consistent with our results here (42) . It is important to note that our analysis does not capture rare higher penetrance mutations, and thus, the observed increased risk of multiple cancers among relatives to prostate cancer cases (32) is likely to at least in part be attributable to rare variants such as BRCA2.
In addition, we examined the genetic correlation between these cancer types and 14 non-cancer diseases and traits. The only genetic correlation between cancer and non-cancer traits that withstood correction for multiple testing was smoking status and lung cancer. The strongest lung cancer susceptibility locus is in the 15q25 region which contains genes encoding the nicotinic acetylcholine receptor subunits CHRNA5, CHRNA3 and CHRNB4 and has also been associated with smoking behavior with associations in the same direction (43) (44) (45) . We found that BMI showed nominally significant genetic correlations with all cancers except ovarian cancer. While BMI showed positive genetic correlation with colorectal, lung and pancreatic cancer, it showed negative genetic correlations with breast and prostate cancer. These results mirror recent Mendelian randomization (MR) studies of BMI and colorectal (46), breast and lung cancer (47, 48) , providing further evidence that obesity is involved in cancer development. An MR study of prostate cancer found a non-significant lower risk associated with a BMI genetic score (Odds ratio (OR)=0.98; 95% CI: 0.96-1.00; p = 0.07) (49) . Although the positive genetic correlation between BMI and lung cancer seems to contradict results from observational studies, the observational association between BMI and lung cancer might be due to residual confounding by smoking (35) . BMI and smoking behavior have been shown to share a genetic basis (r g =0.20, p=8.3x10 -7 ) (22) and further, cell-type enrichment heritability analysis have shown that both smoking behavior and BMI are enriched for central nervous system (CNS)-related cell types.
Therefore, it is possible that smoking and BMI to some extent affect lung cancer risk through the same biological mechanism.
We observed very few genetic correlations with prostate cancer compared with the other cancers of comparable sample size and no genetic correlation with non-cancer traits were >0.1. We also note the lack of genetic correlation between prostate cancer and type 2 diabetes (r g =0.03, 95%
confidence interval: -0.10-0.15, p=0.67). The epidemiological inverse association between prostate cancer and type 2 diabetes is well-documented (50-53) and a previous study showed that 10 out of 36 type 2 diabetes SNPs were associated (2 with increased risk and 8 with decreased risk) with advanced prostate cancer (54) . The different directions of significant prostate cancer associations across type 2 diabetes SNPs are consistent with the lack of genetic correlation (which is sensitive to direction of effects) observed in this study. 
